Matthew L Romo, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurocysticercosis | 23 | 2023 | 88 | 6.340 |
Why?
|
Albendazole | 6 | 2019 | 51 | 1.880 |
Why?
|
Anthelmintics | 7 | 2019 | 83 | 1.800 |
Why?
|
Taenia solium | 4 | 2020 | 28 | 1.360 |
Why?
|
Onchocerciasis | 2 | 2020 | 28 | 1.280 |
Why?
|
HIV Infections | 22 | 2025 | 17533 | 1.190 |
Why?
|
Epilepsy | 8 | 2021 | 3320 | 1.170 |
Why?
|
Oxazines | 3 | 2022 | 358 | 0.990 |
Why?
|
Heterocyclic Compounds, 3-Ring | 3 | 2022 | 295 | 0.960 |
Why?
|
Kenya | 16 | 2025 | 758 | 0.950 |
Why?
|
Education, Special | 2 | 2022 | 86 | 0.950 |
Why?
|
Praziquantel | 2 | 2015 | 34 | 0.930 |
Why?
|
Hunger | 2 | 2016 | 207 | 0.910 |
Why?
|
Mycoplasma genitalium | 1 | 2024 | 13 | 0.900 |
Why?
|
Anti-HIV Agents | 4 | 2024 | 4559 | 0.880 |
Why?
|
Mycoplasma Infections | 1 | 2024 | 120 | 0.870 |
Why?
|
Antibodies, Helminth | 3 | 2020 | 59 | 0.800 |
Why?
|
Pyridones | 3 | 2022 | 816 | 0.790 |
Why?
|
Pharmacists | 2 | 2014 | 260 | 0.760 |
Why?
|
Onchocerca volvulus | 1 | 2020 | 14 | 0.700 |
Why?
|
Chlamydia Infections | 1 | 2024 | 364 | 0.690 |
Why?
|
HIV Integrase Inhibitors | 1 | 2021 | 164 | 0.660 |
Why?
|
Gonorrhea | 1 | 2024 | 354 | 0.650 |
Why?
|
Helminth Proteins | 1 | 2020 | 173 | 0.650 |
Why?
|
Mass Screening | 11 | 2022 | 5446 | 0.590 |
Why?
|
Sexually Transmitted Diseases | 1 | 2024 | 667 | 0.580 |
Why?
|
Piperazines | 3 | 2022 | 2549 | 0.550 |
Why?
|
Dangerous Behavior | 1 | 2016 | 65 | 0.530 |
Why?
|
Health Services Needs and Demand | 2 | 2014 | 1406 | 0.520 |
Why?
|
Motor Vehicles | 9 | 2024 | 280 | 0.520 |
Why?
|
Students | 2 | 2016 | 1734 | 0.510 |
Why?
|
Receptors, Leptin | 1 | 2017 | 355 | 0.490 |
Why?
|
New York City | 4 | 2023 | 733 | 0.470 |
Why?
|
Trypanocidal Agents | 1 | 2014 | 40 | 0.460 |
Why?
|
Ecuador | 4 | 2018 | 62 | 0.450 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 3807 | 0.440 |
Why?
|
Bullying | 1 | 2016 | 234 | 0.430 |
Why?
|
Glycoproteins | 1 | 2020 | 2195 | 0.400 |
Why?
|
Chagas Disease | 1 | 2014 | 163 | 0.400 |
Why?
|
Crime Victims | 1 | 2016 | 348 | 0.400 |
Why?
|
Automobile Driving | 8 | 2024 | 441 | 0.390 |
Why?
|
Emigrants and Immigrants | 1 | 2018 | 549 | 0.380 |
Why?
|
Developmental Disabilities | 1 | 2020 | 1519 | 0.380 |
Why?
|
Choice Behavior | 4 | 2018 | 844 | 0.380 |
Why?
|
Social Stigma | 1 | 2018 | 788 | 0.370 |
Why?
|
Professional Role | 1 | 2014 | 313 | 0.370 |
Why?
|
Cultural Competency | 1 | 2014 | 303 | 0.360 |
Why?
|
Mexico | 4 | 2022 | 777 | 0.350 |
Why?
|
Antigens, Helminth | 2 | 2020 | 67 | 0.340 |
Why?
|
Awareness | 1 | 2014 | 653 | 0.340 |
Why?
|
Seizures | 4 | 2021 | 3000 | 0.330 |
Why?
|
Tuberculosis | 1 | 2022 | 2012 | 0.320 |
Why?
|
Suicidal Ideation | 2 | 2016 | 1461 | 0.320 |
Why?
|
Population Surveillance | 2 | 2017 | 2590 | 0.320 |
Why?
|
Developing Countries | 1 | 2021 | 2911 | 0.320 |
Why?
|
Leptin | 1 | 2017 | 1596 | 0.310 |
Why?
|
Uganda | 3 | 2025 | 1353 | 0.310 |
Why?
|
Self Administration | 3 | 2020 | 385 | 0.300 |
Why?
|
Anticonvulsants | 2 | 2014 | 1921 | 0.280 |
Why?
|
Humans | 64 | 2025 | 765968 | 0.270 |
Why?
|
Bolivia | 2 | 2016 | 22 | 0.270 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 1534 | 0.270 |
Why?
|
Health Surveys | 4 | 2017 | 4056 | 0.260 |
Why?
|
Health Promotion | 1 | 2018 | 2208 | 0.260 |
Why?
|
AIDS Serodiagnosis | 2 | 2018 | 220 | 0.260 |
Why?
|
Androgen Antagonists | 1 | 2015 | 1411 | 0.260 |
Why?
|
Male | 36 | 2025 | 363698 | 0.260 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 1808 | 0.250 |
Why?
|
Exercise | 3 | 2018 | 5937 | 0.250 |
Why?
|
Suicide | 1 | 2016 | 1604 | 0.250 |
Why?
|
Viral Load | 3 | 2025 | 3386 | 0.250 |
Why?
|
HIV | 3 | 2023 | 1585 | 0.240 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3230 | 0.230 |
Why?
|
Prednisone | 3 | 2018 | 1565 | 0.230 |
Why?
|
Poverty | 1 | 2016 | 2714 | 0.220 |
Why?
|
Asymptomatic Infections | 1 | 2025 | 136 | 0.220 |
Why?
|
School Health Services | 2 | 2018 | 387 | 0.220 |
Why?
|
Female | 31 | 2025 | 396112 | 0.210 |
Why?
|
Self Care | 2 | 2019 | 800 | 0.210 |
Why?
|
Africa South of the Sahara | 2 | 2024 | 751 | 0.210 |
Why?
|
Primary Health Care | 2 | 2018 | 4736 | 0.210 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26318 | 0.210 |
Why?
|
Chlamydia trachomatis | 1 | 2024 | 240 | 0.200 |
Why?
|
Electronic Health Records | 2 | 2017 | 4873 | 0.190 |
Why?
|
Serologic Tests | 3 | 2019 | 382 | 0.190 |
Why?
|
Color | 1 | 2022 | 299 | 0.180 |
Why?
|
Neisseria gonorrhoeae | 1 | 2024 | 248 | 0.180 |
Why?
|
Nutrition Surveys | 3 | 2017 | 1741 | 0.180 |
Why?
|
Fruit | 2 | 2016 | 1166 | 0.180 |
Why?
|
Vegetables | 2 | 2016 | 1199 | 0.180 |
Why?
|
Reagent Kits, Diagnostic | 2 | 2019 | 238 | 0.180 |
Why?
|
Benzoxazines | 1 | 2022 | 320 | 0.170 |
Why?
|
Adult | 23 | 2025 | 223044 | 0.170 |
Why?
|
Rifampin | 1 | 2022 | 351 | 0.170 |
Why?
|
Latin America | 2 | 2022 | 416 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4058 | 0.170 |
Why?
|
Young Adult | 9 | 2025 | 59889 | 0.170 |
Why?
|
Health Services Accessibility | 4 | 2023 | 5508 | 0.160 |
Why?
|
Smoking | 1 | 2016 | 9081 | 0.160 |
Why?
|
Interleukin-4 | 1 | 2023 | 1162 | 0.160 |
Why?
|
France | 1 | 2020 | 495 | 0.160 |
Why?
|
Quality of Health Care | 1 | 2014 | 4300 | 0.160 |
Why?
|
Adolescent | 9 | 2024 | 88835 | 0.150 |
Why?
|
Cohort Studies | 6 | 2025 | 41649 | 0.150 |
Why?
|
Endemic Diseases | 1 | 2018 | 189 | 0.140 |
Why?
|
Schools | 2 | 2016 | 1492 | 0.140 |
Why?
|
Depression | 2 | 2017 | 8237 | 0.140 |
Why?
|
Honduras | 1 | 2016 | 39 | 0.140 |
Why?
|
Uruguay | 1 | 2016 | 104 | 0.140 |
Why?
|
Costa Rica | 1 | 2016 | 186 | 0.130 |
Why?
|
Central Nervous System Parasitic Infections | 1 | 2016 | 2 | 0.130 |
Why?
|
Odds Ratio | 2 | 2020 | 9649 | 0.130 |
Why?
|
Alzheimer Disease | 1 | 2017 | 8730 | 0.120 |
Why?
|
Feeding Behavior | 2 | 2018 | 3212 | 0.120 |
Why?
|
Administrative Personnel | 1 | 2016 | 186 | 0.120 |
Why?
|
Sexual Behavior | 1 | 2024 | 2193 | 0.120 |
Why?
|
Killer Cells, Natural | 1 | 2023 | 2210 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2022 | 65188 | 0.110 |
Why?
|
Middle Aged | 13 | 2025 | 223009 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 790 | 0.110 |
Why?
|
Peru | 1 | 2016 | 887 | 0.110 |
Why?
|
Histamine Antagonists | 1 | 2014 | 93 | 0.110 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1787 | 0.110 |
Why?
|
Vaccines | 1 | 2022 | 841 | 0.110 |
Why?
|
Prevalence | 4 | 2025 | 15842 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2023 | 3222 | 0.100 |
Why?
|
Weight Gain | 1 | 2023 | 2355 | 0.100 |
Why?
|
Beverages | 1 | 2018 | 819 | 0.100 |
Why?
|
Animals | 9 | 2020 | 168764 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11083 | 0.100 |
Why?
|
Recurrence | 2 | 2015 | 8501 | 0.100 |
Why?
|
Drug Therapy, Combination | 3 | 2018 | 6309 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4348 | 0.100 |
Why?
|
Fibrinogen | 1 | 2015 | 895 | 0.090 |
Why?
|
Mendelian Randomization Analysis | 1 | 2017 | 1044 | 0.090 |
Why?
|
Dexamethasone | 1 | 2018 | 1963 | 0.090 |
Why?
|
Food Supply | 1 | 2016 | 544 | 0.090 |
Why?
|
Cysts | 1 | 2015 | 684 | 0.090 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7425 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14652 | 0.080 |
Why?
|
Brain | 2 | 2021 | 27171 | 0.080 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15652 | 0.080 |
Why?
|
Drug Interactions | 1 | 2014 | 1417 | 0.080 |
Why?
|
Child, Preschool | 3 | 2022 | 42500 | 0.080 |
Why?
|
Hypercholesterolemia | 1 | 2016 | 1149 | 0.080 |
Why?
|
Diabetes Mellitus | 3 | 2017 | 5891 | 0.080 |
Why?
|
Proton Pump Inhibitors | 1 | 2014 | 553 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7421 | 0.070 |
Why?
|
Nutritional Status | 1 | 2016 | 1620 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8041 | 0.070 |
Why?
|
Dyslipidemias | 1 | 2015 | 869 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 7838 | 0.070 |
Why?
|
Hypertension | 3 | 2017 | 8626 | 0.070 |
Why?
|
Triglycerides | 1 | 2015 | 2441 | 0.070 |
Why?
|
Consensus | 1 | 2016 | 3202 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 2 | 2025 | 2587 | 0.060 |
Why?
|
United States | 4 | 2022 | 72903 | 0.060 |
Why?
|
Child | 4 | 2022 | 80564 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2535 | 0.060 |
Why?
|
Risk Factors | 3 | 2018 | 74840 | 0.060 |
Why?
|
Adiposity | 1 | 2015 | 1890 | 0.060 |
Why?
|
Health Behavior | 1 | 2016 | 2650 | 0.060 |
Why?
|
Pilot Projects | 1 | 2018 | 8733 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1880 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3850 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12056 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 6209 | 0.050 |
Why?
|
Nigeria | 1 | 2025 | 782 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13266 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2015 | 3985 | 0.050 |
Why?
|
Chronic Disease | 1 | 2016 | 9347 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2018 | 22223 | 0.040 |
Why?
|
Blood Glucose | 1 | 2015 | 6424 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2020 | 26346 | 0.040 |
Why?
|
Tanzania | 1 | 2025 | 1407 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 642 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4015 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39193 | 0.040 |
Why?
|
Counseling | 2 | 2017 | 1551 | 0.040 |
Why?
|
Blood Pressure | 1 | 2015 | 8532 | 0.040 |
Why?
|
Goals | 1 | 2024 | 719 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2019 | 20659 | 0.040 |
Why?
|
Immunocompetence | 1 | 2019 | 138 | 0.040 |
Why?
|
Immunologic Tests | 1 | 2019 | 101 | 0.040 |
Why?
|
Epidemics | 1 | 2024 | 514 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 30260 | 0.040 |
Why?
|
Infant | 1 | 2020 | 36386 | 0.040 |
Why?
|
International Cooperation | 1 | 2024 | 1432 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 16047 | 0.040 |
Why?
|
Rural Population | 2 | 2019 | 2317 | 0.030 |
Why?
|
Aged | 3 | 2019 | 171117 | 0.030 |
Why?
|
Occupations | 1 | 2019 | 516 | 0.030 |
Why?
|
Antiparasitic Agents | 1 | 2016 | 41 | 0.030 |
Why?
|
Mouth | 1 | 2018 | 381 | 0.030 |
Why?
|
Granuloma | 1 | 2017 | 327 | 0.030 |
Why?
|
Gait Disorders, Neurologic | 1 | 2018 | 246 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 664 | 0.030 |
Why?
|
Sexual Partners | 1 | 2020 | 804 | 0.030 |
Why?
|
Headache Disorders | 1 | 2018 | 152 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18071 | 0.030 |
Why?
|
Muscle Weakness | 1 | 2018 | 413 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2019 | 59489 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2020 | 81514 | 0.030 |
Why?
|
Obesity | 1 | 2016 | 13076 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14751 | 0.030 |
Why?
|
Saliva | 1 | 2019 | 851 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 40065 | 0.030 |
Why?
|
Prognosis | 1 | 2014 | 29922 | 0.030 |
Why?
|
Immunization | 1 | 2017 | 1219 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8703 | 0.030 |
Why?
|
Heart Failure | 1 | 2014 | 11840 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4850 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2017 | 778 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3426 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1203 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3139 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20124 | 0.020 |
Why?
|
Urban Population | 1 | 2016 | 2040 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3685 | 0.020 |
Why?
|
Influenza, Human | 1 | 2017 | 1539 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2017 | 3832 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 21480 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2018 | 12437 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10808 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13632 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18380 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54802 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36532 | 0.010 |
Why?
|